BOLT

Bolt Biotherapeutics, Inc.

0.75 USD
+0.01 (+2.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Bolt Biotherapeutics, Inc. stock is down -0.57% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 July’s closed higher than June.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.